Bariatric Surgery Outperforms GLP-1 Drugs at Correcting Tissue-Remodeling Enzymes in Obesity | Research

The takeaway

Bariatric surgery consistently reduces harmful MMP-9 levels and normalizes MMP-2 activity in obesity, while GLP-1/GIP drugs achieve weight loss but lack strong evidence for direct effects on these tissue-remodeling enzymes.

MMP-9 consistently reduced
by bariatric surgery but not yet demonstrated for GLP-1/GIP drugs, despite comparable weight loss outcomes

What the researchers found

Bariatric surgery consistently reduces MMP-9 levels and normalizes MMP-2 activity in obese patients, contributing to improved extracellular matrix integrity, reduced inflammation, and enhanced insulin sensitivity. These changes reflect a correction of the tissue-remodeling dysfunction characteristic of obesity.

GLP-1 receptor agonists and dual GLP-1/GIP agonists achieve substantial weight loss and glycemic control, but current evidence regarding their direct effects on MMP activity remains limited. This gap suggests that the tissue-level effects of pharmacotherapy may not fully replicate those of surgery, despite comparable weight loss outcomes.

Why it matters

This review highlights an underappreciated dimension of obesity treatment: beyond weight loss and blood sugar, the body's tissue-remodeling machinery needs to recover. If GLP-1 drugs don't fully correct MMP dysregulation the way surgery does, patients might still carry risk for obesity-related tissue damage even after losing weight pharmacologically. This could influence how we evaluate and compare obesity treatments.

How the study worked

Narrative review analyzing literature from PubMed, Scopus, and Web of Science (2015-2024). The authors focused on studies evaluating MMPs, inflammation markers, and metabolic parameters in the context of bariatric surgery and GLP-1/GIP-based pharmacotherapy for obesity.

What this study cannot tell us

This is a narrative review, not a systematic review or meta-analysis, which may introduce selection bias in the literature covered. The limited evidence on GLP-1/GIP effects on MMPs makes direct comparison with surgery difficult. MMP measurements vary across studies in terms of assay methods and tissue sources. The review does not distinguish between different types of bariatric surgery.

How to read the evidence

This is a narrative review synthesizing literature from 2015-2024. While it provides a useful comparative perspective, it is not a systematic review and the evidence for pharmacotherapy's effects on MMPs is acknowledged as limited.

When this study was published

Published in 2025, this review addresses a timely question as GLP-1/GIP drugs increasingly compete with bariatric surgery for obesity treatment.

The bigger picture

As GLP-1 and dual-agonist drugs increasingly compete with bariatric surgery for obesity treatment, understanding their effects beyond weight and blood sugar becomes important. MMPs are involved in cardiovascular disease, fibrosis, and cancer — all obesity-related conditions. If surgical and pharmacological weight loss differ in their effects on tissue remodeling, this could have implications for long-term health outcomes.

Questions still open

Do GLP-1/GIP drugs eventually normalize MMP activity with longer treatment duration, or is this a fundamental difference from surgery?
Could MMP levels serve as a biomarker to assess whether obesity treatment is addressing tissue-level damage?
Would combining pharmacotherapy with targeted MMP modulation improve tissue outcomes beyond weight loss alone?

Common questions

What are MMPs and why do they matter in obesity?

Matrix metalloproteinases (MMPs) are enzymes that remodel connective tissue throughout the body. In obesity, they become dysregulated — MMP-9 increases (driving inflammation and tissue damage) while MMP-2 becomes abnormal. Correcting this dysfunction is important for reducing obesity's long-term damage to the heart, blood vessels, and other organs.

Does this mean surgery is better than GLP-1 drugs for obesity?

Not necessarily overall, but this review suggests surgery may be better at correcting tissue-level damage as measured by MMP activity. GLP-1 drugs still achieve significant weight loss and metabolic benefits. The question is whether the tissue-remodeling differences matter for long-term outcomes — more research is needed.

Read the original research

Modulating Matrix Metalloproteinase Activity in Obesity: Comparative Effects of Bariatric Surgery and GLP-1/GIP-Based Pharmacotherapy.

Journal of clinical medicine, 14(21)

View on PubMed ↗Publisher’s paper ↗

Citation

Wiśniewski, Konrad; Choromańska, Barbara; Maciejczyk, Mateusz; Dadan, Jacek; Myśliwiec, Piotr. (2025). Modulating Matrix Metalloproteinase Activity in Obesity: Comparative Effects of Bariatric Surgery and GLP-1/GIP-Based Pharmacotherapy.. Journal of clinical medicine, 14(21). https://doi.org/10.3390/jcm14217648